Collinson Howe Venture Partners

Description

Collinson Howe Venture Partners, Inc. (“CHVP”) is a privately held private equity and venture capital manager. We serve as active directors of our portfolio companies. Since 1990, we have invested in over 100 companies, diversified across the entire healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, diagnostics, services, HCIT, and genomics. We have been start-up and early stage investors in companies now valued collectively at well over $125 billion, including Incyte Pharmaceuticals, Alexion Pharmaceuticals, American Renal Associates, Odyssey Healthcare, Ascend Health, and Celgene. We manage outside capital typically via long-term limited partnerships. Prior funds managed are Schroder Ventures Limited Partnership and US Trust, Schroders Inc. US portfolios, Biotechnology Investment Group LLC, CHL Medical Partners I, I, & III, and HealthInvest Equity Partners LP. Today, our primary focus is on tech-enabled healthcare services. Examples include Ambra Health and Genome Medical.

Collinson Howe Venture Partners is a long-standing early-stage healthcare venture capital firm that backs startup and growth-stage companies across biotech, pharma, medical devices, diagnostics, HCIT, and tech-enabled healthcare services — it invests in companies, not in acquiring or rolling up clinical practice platforms.

CHVP/CHL Medical Partners is an early-stage venture capital and growth-equity investor focused on healthcare services startups (e.g. Ambra Health, Genome Medical) and biotech/pharma product companies — it is a product/startup VC, not a platform buyout or control-equity acquirer of healthcare-services platforms, and has no dental practice acquisition mandate.

enriched 2026-05-05

Financials